Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Total Liabilities (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Total Liabilities for 5 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 56.04% to $6.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.9 million, a 56.04% increase, with the full-year FY2025 number at $9.6 million, changed N/A from a year prior.
  • Total Liabilities was $6.9 million for Q4 2025 at Neuphoria Therapeutics, down from $14.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $14.8 million in Q3 2025 to a low of $4.4 million in Q4 2024.
  • A 4-year average of $7.4 million and a median of $6.3 million in 2022 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: grew 9.52% in 2023, then soared 153.7% in 2025.
  • Neuphoria Therapeutics' Total Liabilities stood at $6.0 million in 2022, then rose by 9.52% to $6.6 million in 2023, then crashed by 32.9% to $4.4 million in 2024, then surged by 56.04% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Total Liabilities are $6.9 million (Q4 2025), $14.8 million (Q3 2025), and $9.6 million (Q2 2025).